HGS v Eli Lilly dispute explained
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

HGS v Eli Lilly dispute explained

The UK’s Supreme Court will next week hear a case concerning whether the UK has correctly followed European patent law on industrial application

The case, Human Genome Sciences (HGS) v Eli Lilly, involves a split between the England & Wales Court of Appeal and the EPO Technical Board of Appeal (TBA).

In the case, the UK courts have revoked HGS's patent for the Neutrokine-α protein - even though the appellant's amended set of claims had been accepted by the TBA (decision T18/09).

The Maryland pharmaceutical company's patent covers the nucleotide and amino acid sequence of a specific cytokine protein ligand from the TNF (tissue necrosis factor) superfamily and antibodies to the ligand.

The protein was identified first by HGS, and later by others, in the 1990s using bioinformatics. Neutrokine-α is just one of a number of names given to the protein coded by the disclosed nucleotide sequence.

The patent was filed at the EPO in 1996 and granted in August 2005. Since filing the patent, HGS has been developing a monoclonal antibody to Neutrokine-α, which is in clinical trials.

Indianapolis-based pharmaceutical company Lilly has reportedly spent $50 million developing its own monoclonal antibody to Neutrokine-α and plans to spend another $250 million bringing it to the clinic.

In 2006, Lilly filed an opposition at the EPO, and a counter claim for revocation at the England & Wales High Court, essentially stating that the patent lacked an inventive step and constituted a claim to an arbitrary member of the TNF ligand superfamily without conceivable industrial applicability at the time of filing.

The case is thought to be one of the few examples where parallel litigation proceedings have been filed and cooperative procedures put in place to fast track the case through the EPO opposition procedure and the UK courts.

In 2008 at the High Court, Mr Justice Kitchin held that all claims in the patent were invalid on three grounds: they were not susceptible of industrial application, they were insufficiently disclosed and they were obvious because of a lack of technical contribution. He therefore revoked the patent.

The equivalent outcome was reached in 2008 following EPO oral proceedings. But in 2009, following the submission of more restrictive claims, the EPO's TBA held the patent valid (T18/09).

However, at the UK Court of appeal, three judges including Lord Justice Jacob ruled that the proposed uses for Neutrokine-α, as outlined in the patent, were not plausible at the time of filing and were ahead of a research programme to determine feasible industrial uses for the protein.

Consequently, despite the proposed amended claims, the patent was essentially deemed not to comply with Article 57 of the European Patent Convention (EPC), which states that the invention must be capable of industrial application.

Regarding the apparent clash of the ruling with decision T18/09 of the TBA, Jacob stated that the EPO was working with different evidence and that the UK courts were not bound to follow the TBA's findings of fact or give deference to them.

The Supreme Court has been asked to rule whether the Court of Appeal correctly applied the principles of law established by the EPO relating to Article 57 of the EPC and whether the amended claims are sufficient to maintain the patent under UK law.

The case is expected to last three days from July 18 to 20. Of the five Lord Justices allocated, Lord Justice Neuberger has the most experience with patent cases and is best known for his landmark ruling in the software patent case Symbian v UK-IPO in which the court ruled in favour of Symbian's software patent application.

In that ruling, Lord Neuberger stated that "it was desirable as far as possible to read the law so that the UK-IPO and the EPO came to similar decisions".

more from across site and ros bottom lb

More from across our site

A 36-member team from Zhong Lun Law Firm, including six partners, will join the newly formed East IP Group
The Delhi High Court sided with Ericsson against Indian smartphone maker Lava, bringing the companies' nine-year dispute to a close
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Tennessee has passed the ELVIS Act, a law that fights against AI models that mimic the voice and likeness of music artists
Rob Stien, chief communications and public policy officer at InterDigital, says the EU has forgotten innovators while trying to solve an issue that doesn’t exist
As Australia’s Qantm IP leans towards being acquired by a private equity company, sources discuss what it could mean for IP firms
Law firms that are conscious of their role in society are more likely to win work, according to a survey of over 23,000 in-house professionals
Nghiem Xuan Bac Pham, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices
Douglas Leite and two of his colleagues were intrigued by Bhering Advogados’s mission to grow its patent litigation practice
Each week Managing IP speaks to a different IP practitioner about their life and career
Gift this article